Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Bownes

Showing results (21-30 of 41) with videos related to

Pageof 5
Sort By:
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 30, 2016
Real-time in vivo dosimetry in high dose rate prostate brachytherapyJosh Mason, Arielle Mamo, Bashar Al-Qaisieh, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 26, 2007
Comprehensive I-125 multi-seed comparison for prostate brachytherapy: dosimetry and visibility analysisBashar Al-Qaisieh, David W Smith, Elizabeth Brearley, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 16, 2004
High dose rate afterloading intraluminal brachytherapy for advanced inoperable rectal carcinomaPeter J Hoskin, Sandra M de Canha, Peter Bownes, et al.
Brachytherapy|September 24, 2023
Conformal 3D computed tomography planned endoluminal brachytherapy for the local control of esophageal cancerChristopher M Jones, Annabel Lyles, Peter Bownes, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 3, 2016
Modelling second malignancy risks from low dose rate and high dose rate brachytherapy as monotherapy for localised prostate cancerLouise Murray, Joshua Mason, Ann M Henry, et al.
Archives of Gynecology and Obstetrics|July 9, 2014
Assessment of uterus position as a surrogate for high-risk clinical target volume with respect to the applicator position for multiple fractions of brachytherapy in cervical cancerRachel Cooper, Elizabeth Brearley, Pervin Hurmuz, et al.
International Journal of Radiation Oncology, Biology, Physics|June 23, 2009
Correlation between pre- and postimplant dosimetry for iodine-125 seed implants for localized prostate cancerBashar Al-Qaisieh, Thelma Witteveen, Brendan Carey, et al.
Journal of Contemporary Brachytherapy|January 13, 2021
Ten-year longitudinal health-related quality of life following iodine-125 brachytherapy monotherapy for localized prostate cancerFinbar Slevin, Brinda Sethugavalar, Bashar Al-Qaisieh, et al.
International Journal of Radiation Oncology, Biology, Physics|December 17, 2009
Outcomes following iodine-125 monotherapy for localized prostate cancer: the results of leeds 10-year single-center brachytherapy experienceAnn M Henry, Bashar Al-Qaisieh, Kathy Gould, et al.
International Journal of Radiation Oncology, Biology, Physics|May 5, 2015
Dosimetry Modeling for Focal Low-Dose-Rate Prostate BrachytherapyBashar Al-Qaisieh, Josh Mason, Peter Bownes, et al.
Pageof 5

Showing results (21-30 of 41) with videos related to

Sort By:
Pageof 5
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 30, 2016
Real-time in vivo dosimetry in high dose rate prostate brachytherapyJosh Mason, Arielle Mamo, Bashar Al-Qaisieh, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 26, 2007
Comprehensive I-125 multi-seed comparison for prostate brachytherapy: dosimetry and visibility analysisBashar Al-Qaisieh, David W Smith, Elizabeth Brearley, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 16, 2004
High dose rate afterloading intraluminal brachytherapy for advanced inoperable rectal carcinomaPeter J Hoskin, Sandra M de Canha, Peter Bownes, et al.
Brachytherapy|September 24, 2023
Conformal 3D computed tomography planned endoluminal brachytherapy for the local control of esophageal cancerChristopher M Jones, Annabel Lyles, Peter Bownes, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 3, 2016
Modelling second malignancy risks from low dose rate and high dose rate brachytherapy as monotherapy for localised prostate cancerLouise Murray, Joshua Mason, Ann M Henry, et al.
Archives of Gynecology and Obstetrics|July 9, 2014
Assessment of uterus position as a surrogate for high-risk clinical target volume with respect to the applicator position for multiple fractions of brachytherapy in cervical cancerRachel Cooper, Elizabeth Brearley, Pervin Hurmuz, et al.
International Journal of Radiation Oncology, Biology, Physics|June 23, 2009
Correlation between pre- and postimplant dosimetry for iodine-125 seed implants for localized prostate cancerBashar Al-Qaisieh, Thelma Witteveen, Brendan Carey, et al.
Journal of Contemporary Brachytherapy|January 13, 2021
Ten-year longitudinal health-related quality of life following iodine-125 brachytherapy monotherapy for localized prostate cancerFinbar Slevin, Brinda Sethugavalar, Bashar Al-Qaisieh, et al.
International Journal of Radiation Oncology, Biology, Physics|December 17, 2009
Outcomes following iodine-125 monotherapy for localized prostate cancer: the results of leeds 10-year single-center brachytherapy experienceAnn M Henry, Bashar Al-Qaisieh, Kathy Gould, et al.
International Journal of Radiation Oncology, Biology, Physics|May 5, 2015
Dosimetry Modeling for Focal Low-Dose-Rate Prostate BrachytherapyBashar Al-Qaisieh, Josh Mason, Peter Bownes, et al.
Pageof 5